 |
Indication & Dosage |
| |
| |
| Oral |
| PALLIATIVE TREATMENT OF PROSTATIC CARCINOMA |
| Adult:
250 mg tid preferably at least 3 days before gonadorelin analogue treatment. |
|
| |
|
| Administration |
May be taken with or without food. |
| |
|
| Precautions |
Perform liver function tests before starting treatment and at regular intervals. Treatment is not recommended in patients whose ALT values exceed twice the upper limit of normal. Regular assessment of prostate specific antigen level may help to monitor disease progression. Advise patient against discontinuing drug on their own. Exercise caution in patients with cardiac disease. |
| |
|
| Adverse Drug Reactions |
Hot flushes, loss of libido, impotence, gynaecomastia, nausea, vomiting, diarrhoea, increased appetite, sleep disturbances, skin reactions, anaemias, headache, dizziness, malaise, anxiety, hypertension, gastric and chest pain, oedema, blurred vision, hepatitis, jaundice, rash, thirst, pruritus, SLE-like syndrome, drowsiness, confusion, depression, nervousness. |
| |
|
| Interactions |
Increased prothrombin time in patients on long-term warfarin treatment. |
| |
|
|
|
